HealthResJ, health, medicine, nursing, research https://ejournals.epublishing.ekt.gr/index.php/HealthResJ/sitemap

Familial hypercholesterolemia. Perspectives on FH registry systems


Published: Oct 10, 2022
Keywords:
Familial hypercholesterolemia perspectives registry systems
Niki Pavlatou
Olga Kadda
Christina Marvaki
Genovefa Kolovou
Abstract

Familial Hypercholesterolemia (FH) is a genetic cause of premature Cardiovascular Disease (CVD) which is the leading cause of morbidity and mortality worldwide. In Greece, it is estimated that 90% of patients remain undiagnosed. Patients with FH are at high risk for cardiovascular events, peripheral arterial disease, stroke and death at a young age. Therefore, early detection of these is important for the implementation of appropriate preventive measures. Patient medical records are a powerful tool for recording and monitoring the disease and promoting clinical practices, thus helping to improve outcomes and reduce the cost of healthcare. Simultaneously with the registers, patient-centered management, multidisciplinary teamwork, involvement of primary care physicians, patient networks and support teams are required. Of most importance is the Greek online register system of people with familial hypercholesterolemia, by the Hellenic Atherosclerosis Society in collaboration with major hospital centers and the Hellenic College of Atherosclerosis Treatment registration system in the community. The purpose is to find people who are suffering from FH, to diagnose, to educate them and to put them under treatment and follow-up. In conclusion, effective care of patients with dyslipidemia requires: a) detailed evaluation of medical history, b) clinical and laboratory tests, and c) patient education programs regarding lifestyle changes and disease management. The above strategies of care will help reduce time and cost of medical treatment, obtain better clinical outcome and improve patients’ quality of life.

Article Details
  • Section
  • Brief Report
Downloads
Download data is not yet available.
References
El Aziz S, Chadli A, El Ghomari H, Farouqi A. Autosomal recessive hypercholesterolaemia in a Morrocan family due to a mutation of the G266C LDL receptor. BMJ Case Rep 2012;2012:bcr0220125717.
Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 2017;7(9):e016461.
De Ferranti SD, Rodday ΑΜ, Mendelson ΜΜ, Wong JB, Leslie LK, Sheldrick RC. Incidence of FH in USA Circula-tion 2016;133: 1067-1072.
Di Taranto MD, Giacobbe C, Fortunato G. Familial hyper-cholesterolemia: A complex genetic disease with variable phenotypes. Eur J Med Genet.2020 Apr;63(4):103831. doi: 10.1016/j.ejmg.2019.103831.
Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R. Identification and management of familial hypercholester-olaemia: what does it mean to primary care? Br J Gen Pract 2009; 59: 773-6.
Damgaard D, Larsen ML, Nissen PH, et al The relationship of modecular genetic to clinical diagnosis of familial hy-percholesteronaimia in a Danish population. Atherosclero-sis 2005; 180:155-60.
Wiegman A, Rodenburg J, de Jongh S, et al . Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003; 107:1473-8.
Jackler RK, Brackmann DE. Xanthoma of the temporal bone and skull base. Am J Otol 1987;8:111-115.
Rallidis LS, Iordanidis D, Iliodromitis E. The value of physical signs in identifying patients with familial hypercholesterol-emia in the era of genetic testing. J Cardiol. 2020;76(6):568-572. doi:10.1016/j.jjcc.2020.07.005
Bianconi V, Banach M, Pirro M; International Lipid Expert Panel (ILEP). Why patients with familial hypercholesterole-mia are at high cardiovascular risk? Beyond LDL-C lev-els.Trends Cardiovasc Med. 2021 May;31(4):205-215. doi: 10.1016/j.tcm.2020.03.004. Epub 2020 Mar 12.
Anagnostis P, Rizos CV, Skoumas I, Rallidis L, Tziomalos K, Skalidis E, Kotsis V, Doumas M, Kolovou G, Sfikas G, Bili-anou E, Koutagiar I, Agapakis D, Zacharis E, Antza C, Kou-maras C, Boutari C, Liamis G, LiberopoulosEN. Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH.Curr Pharm Des. 2021;27(21):2537-2544. doi: 10.2174/1381612827666210216151645.
Humphries SE, Cooper JA, Seed M, Capps N, Durrington PN, Jones B, McDowell IFW, Soran H, Neil HAW; Coro-nary heart disease mortality in treated familial hypercholes-terolaemia: Update of the UK Simon Broome FH register.Atherosclerosis 2018 Jul;274:41 46. doi:10.1016/j.atherosclerosis.2018.04.040.
Raal FJ, Hovingh GK, Catapano AL. Familial hypercholes-terolemia treatments: Guidelines and new thera-pies.Atherosclerosis. 2018 Oct;277:483-492. doi: 10.1016/j.atherosclerosis.2018.06.859.
Jackson CL, Huschka T, Borah B, et al. Cost-effectiveness of cascade genetic testing for familial hypercholesterolemia in the United States: A simulation analysis. Am J Prev Cardiol. 2021;8:100245. Published 2021 Aug 15. doi:10.1016/j.ajpc.2021.100245
Pelczarska A, Jakubczyk M, Jakubiak-Lasocka J, Banach M, Myśliwiec M, Gruchała M, Niewada M. The cost-effectiveness of screening strategies for familial hypercho-lesterolaemia in Poland. Atherosclerosis. 2018 Mar;270:132-138. doi: 10.1016/j.atherosclerosis.2018.01.036.
Stoekenbroek RM, Kastelein JJP, Hovingh GK. Can we af-ford not to screen for FH?. Eur Heart J. 2017;38(23):1840-1842. doi:10.1093/eurheartj/ehx197
Kolovou G., "Familial Hypercholesterolemia - Cytosterole-mia" INFO HEALTH Publications, pp. 14-59, 100, 104, 73-74, 85-86, 253, 2012.
Pirillo A, Garlaschelli K, Arca M, et al. Spectrum of muta-tions in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atheroscler Suppl. 2017;29:17-24. doi:10.1016/j.atherosclerosissup.2017.07.002
Nair P. Brown and Goldstein: the cholesterol chroni-cles. Proc Natl Acad Sci U S A. 2013;110(37):14829-14832. doi:10.1073/pnas.1315180110
Sun XM, Eden ER, Tosi I, et al. Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unu-sually severe dominant hypercholesterolaemia. Hum Mol Genet. 2005;14(9):1161-1169. doi:10.1093/hmg/ddi128
Singh S, Bittner V. Familial hypercholesterolemia--epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015;17(2):482. doi:10.1007/s11883-014-0482-5
Pitsavos C., Panagiotakos DB., Chrysohoou C., Stefanadis C. Epidemiology of Cardiovascular risk factors in Greece, aims, design and baseline characteristics of the ATTICA study. BMC Public Health 2003; 3:32.
Costa J., Borges M, Oliveira E, Gouveia M, Carneiro AV: In-cidence and prevalence of hypercholesterolemia in Portu-gal: a systemic rewie. Part I. Rev Port Cardiol 2003,22: 569-77.
Gabriel R, Saiz C, Susi R, Alonso M, Vega S, Lopez I, Cruz Garnenal MM, Gomez - Gerique JA, Porres A, Muniz J, Epi-cardian tudy: Epidemiology of lipid profile of the Spanish elderly population: the epicardian study Med Clin (Barc) 2004: 122: 605-9.
Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes heterozygous FH: a HUGE prevalence review. Am j Epidemiol 2004;: 407-420
Pavlatou, N., Rovina, N., Toylia, G., Kadda, O., Marvaki, C., Kapadochos, T., Kolovou, G., & Koutsoukou, A. (2021). Prevalence of familial hypercholesterolemia in Attica re-gion, Greece. Health & Research Journal, 7(1), 26–38.
Qureshi N, Humphries SE, Seed M, Rowlands P, Minhas R. Identification and management of familial hypercholester-olaemia: what does it mean to primary care? Br J Gen Pract 2009; 59: 773-6.
Damgaard D, Larsen ML, Nissen PH, et al The relationship of modecular genetic to clinical diagnosis of familial hy-percholesteronaimia in a Danish population. Atherosclero-sis 2005; 180: 155-60.
Amerizadeh A, Javanmard SH, Sarrafzadegan N, Vaseghi G. Familial Hypercholesterolemia (FH) Registry Worldwide: A Systematic Review [published online ahead of print, 2021 Sep 24]. Curr Probl Cardiol. 2021;100999. doi:10.1016/j.cpcardiol.2021.100999
Vrablík M, Vaclová M, Tichý L, et al. Familial hypercholes-terolemia in the Czech Republic: more than 17 years of sys-tematic screening within the MedPed project. Physiol Res. 2017;66(Suppl 1):S1-S9. doi:10.33549/physiolres.933600
Mata P, Alonso R, Pérez-Jiménez F. Screening for familial hypercholesterolemia: a model for preventive medicine. Rev Esp Cardiol (Engl Ed). 2014;67(9):685-688. doi:10.1016/j.rec.2014.01.015
Nordestgaard BG, Chapman MJ, Humphries SE, et al. Famil-ial hypercholesterolaemia is underdiagnosed and under-treated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society [published correction appears in Eur Heart J. 2020;41(47):4517]. Eur Heart J. 2013;34(45):3478-90a. doi:10.1093/eurheartj/eht273
Ross J. Educating patients about familial hypercholesterol-emia: the role of the cardiovascular nurse. J Cardiovasc Nurs. 2013;28(2):102. doi:10.1097/JCN.0b013e3182834015
Most read articles by the same author(s)